ATE298346T1 - Verbindungen zur behandlung von abnormaler glomerularer filtration, patent ductus arteriosus und osteoporosis - Google Patents
Verbindungen zur behandlung von abnormaler glomerularer filtration, patent ductus arteriosus und osteoporosisInfo
- Publication number
- ATE298346T1 ATE298346T1 AT00984691T AT00984691T ATE298346T1 AT E298346 T1 ATE298346 T1 AT E298346T1 AT 00984691 T AT00984691 T AT 00984691T AT 00984691 T AT00984691 T AT 00984691T AT E298346 T1 ATE298346 T1 AT E298346T1
- Authority
- AT
- Austria
- Prior art keywords
- osteoporosis
- ductus arteriosus
- compounds
- treatment
- glomerular filtration
- Prior art date
Links
- 208000001132 Osteoporosis Diseases 0.000 title abstract 2
- 238000011282 treatment Methods 0.000 title abstract 2
- 230000002159 abnormal effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 230000024924 glomerular filtration Effects 0.000 title 1
- 208000003278 patent ductus arteriosus Diseases 0.000 title 1
- 210000003017 ductus arteriosus Anatomy 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 208000018035 Dental disease Diseases 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 102000008866 Prostaglandin E receptors Human genes 0.000 abstract 1
- 108010088540 Prostaglandin E receptors Proteins 0.000 abstract 1
- 208000014151 Stomatognathic disease Diseases 0.000 abstract 1
- 210000000988 bone and bone Anatomy 0.000 abstract 1
- 230000001605 fetal effect Effects 0.000 abstract 1
- 238000001914 filtration Methods 0.000 abstract 1
- 239000012530 fluid Substances 0.000 abstract 1
- 229910052500 inorganic mineral Inorganic materials 0.000 abstract 1
- 210000003734 kidney Anatomy 0.000 abstract 1
- 239000011707 mineral Substances 0.000 abstract 1
- 239000000816 peptidomimetic Substances 0.000 abstract 1
- 230000002028 premature Effects 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 239000002464 receptor antagonist Substances 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Toxicology (AREA)
- Rheumatology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pipe Accessories (AREA)
- Flanged Joints, Insulating Joints, And Other Joints (AREA)
- Joints With Sleeves (AREA)
- Water Treatment By Sorption (AREA)
- Water Treatment By Electricity Or Magnetism (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45548399A | 1999-12-06 | 1999-12-06 | |
| PCT/CA2000/001445 WO2001042281A1 (en) | 1999-12-06 | 2000-12-06 | Compositions for treating abnormalities in glomerular filtration, patent ductus arteriosus and osteoporosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE298346T1 true ATE298346T1 (de) | 2005-07-15 |
Family
ID=23808998
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT00984691T ATE298346T1 (de) | 1999-12-06 | 2000-12-06 | Verbindungen zur behandlung von abnormaler glomerularer filtration, patent ductus arteriosus und osteoporosis |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US7442763B2 (enExample) |
| EP (1) | EP1244693B1 (enExample) |
| JP (1) | JP2003516417A (enExample) |
| AT (1) | ATE298346T1 (enExample) |
| AU (1) | AU784630B2 (enExample) |
| CA (1) | CA2396739A1 (enExample) |
| DE (1) | DE60020997T2 (enExample) |
| ES (1) | ES2246915T3 (enExample) |
| MX (1) | MXPA02005626A (enExample) |
| NZ (1) | NZ520762A (enExample) |
| WO (1) | WO2001042281A1 (enExample) |
| ZA (1) | ZA200205795B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040235749A1 (en) * | 1999-09-15 | 2004-11-25 | Sylvain Chemtob | G-protein coupled receptor antagonists |
| AU784630B2 (en) | 1999-12-06 | 2006-05-18 | Hopital Sainte-Justine | Compositions for treating abnormalities in glomerular filtration, patent ductus arteriosus and osteoporosis |
| WO2003030911A1 (en) * | 2001-10-08 | 2003-04-17 | Medical Research Council | Use of prostaglandin e synthase inhibitors, or ep2 or ep4 receptor antagonists, in the treatment of a pathological condition of the uterus |
| EP1450813B1 (en) * | 2001-10-31 | 2007-08-29 | Medical Research Council | Antagonists of prostaglandin receptors ep2 and/or ep4 for the treatment of menorrhagia |
| US7414029B2 (en) | 2002-05-23 | 2008-08-19 | Theratechnologies, Inc. | Antagonistic peptides of prostaglandin E2 receptor subtype EP4 |
| JP2006506327A (ja) * | 2002-05-23 | 2006-02-23 | セラテクノロジーズ インコーポレイティド | プロスタグランジンｅ２の受容体サブタイプｅｐ４のアンタゴニスト・ポリペプチド |
| EP1878741A3 (en) * | 2002-05-23 | 2008-02-20 | Theratechnologies Inc. | Antagonistic peptides of prostaglandin E2 receptor subtype EP4 |
| WO2004073589A2 (en) * | 2003-02-24 | 2004-09-02 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with g-protein coupled receptor prostaglandin e2 ep4 (prostaglandin e2 ep4) |
| US8618054B2 (en) * | 2004-05-05 | 2013-12-31 | Valorisation-Rechereche Société en Commandite | Interleukin-1 receptor antagonists, compositions, and methods of treatment |
| WO2013167582A1 (en) | 2012-05-09 | 2013-11-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for prevention or treatment of chronic obstructive pulmonary disease |
| US12036286B2 (en) | 2021-03-18 | 2024-07-16 | Seagen Inc. | Selective drug release from internalized conjugates of biologically active compounds |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9019120D0 (en) * | 1990-09-01 | 1990-10-17 | Beecham Group Plc | Novel compounds |
| AU4855393A (en) * | 1992-09-10 | 1994-03-29 | New York University | Polypeptides of g-coupled receptor proteins, and compositions and methods thereof |
| CA2157510A1 (en) * | 1993-03-05 | 1994-09-15 | Howard M. Grey | Hla-a2.1 binding peptides and their uses |
| US5869281A (en) | 1993-06-25 | 1999-02-09 | Merck Frosst Canada Inc. | DNA encoding prostaglandin receptor FP |
| US5605814A (en) * | 1993-08-31 | 1997-02-25 | Merck Frosst Canada Inc. | DNA encoding human prostaglandin receptor EP2 |
| AU685187B2 (en) * | 1993-10-29 | 1998-01-15 | Incyte Pharmaceuticals, Inc. | Chimeric proteins including protease nexin-1 variants |
| EP0756604A1 (en) * | 1994-04-22 | 1997-02-05 | THE UNITED STATES OF AMERICA, as represented by the Secretary of the Department of Health and Human Services | Melanoma antigens |
| US5866679A (en) * | 1994-06-28 | 1999-02-02 | Merck & Co., Inc. | Peptides |
| WO1996006856A1 (en) * | 1994-08-31 | 1996-03-07 | Robert Webber | Dopamine receptor peptides and anti-peptide antibodies |
| CN1160115C (zh) * | 1994-12-12 | 2004-08-04 | 奥默罗斯公司 | 用于抑制疼痛,炎症和痉挛的冲洗液和方法 |
| EP0870198A4 (en) | 1995-01-25 | 2001-04-04 | Cor Therapeutics Inc | RECOMBINANT C140 RECEPTOR, ITS AGONISTS AND ANTAGONISTS, AND NUCLEIC ACIDS ENCODING THE RECEPTOR |
| US5877155A (en) * | 1995-03-17 | 1999-03-02 | The Research Foundation Of State University Of New York | Mimotopes and anti-mimotopes of human platelet glycoprotein Ib/IX |
| US6117839A (en) * | 1995-06-07 | 2000-09-12 | Gensci Regeneration Sciences, Inc. | Bone stimulating factor |
| AU2658897A (en) * | 1996-03-21 | 1997-10-10 | Epimmune, Inc. | Hla-a2.1 binding peptides and their uses |
| WO1998010651A1 (en) * | 1996-09-12 | 1998-03-19 | Merck & Co., Inc. | Conjugates useful in the treatment of prostate cancer |
| US5955575A (en) * | 1997-12-22 | 1999-09-21 | Hopital Sainte-Justine | Antagonists of G-protein-coupled receptor |
| AUPP320998A0 (en) * | 1998-04-27 | 1998-05-21 | Walter And Eliza Hall Institute Of Medical Research, The | Tyrosine phosphatase IA-2 T-cell epitopes |
| US6984719B1 (en) * | 1998-09-17 | 2006-01-10 | Hospital Sainte-Justine | Peptide antagonists of prostaglandin F2α receptor |
| US20040235749A1 (en) * | 1999-09-15 | 2004-11-25 | Sylvain Chemtob | G-protein coupled receptor antagonists |
| AU784630B2 (en) | 1999-12-06 | 2006-05-18 | Hopital Sainte-Justine | Compositions for treating abnormalities in glomerular filtration, patent ductus arteriosus and osteoporosis |
-
2000
- 2000-12-06 AU AU21340/01A patent/AU784630B2/en not_active Ceased
- 2000-12-06 AT AT00984691T patent/ATE298346T1/de not_active IP Right Cessation
- 2000-12-06 ES ES00984691T patent/ES2246915T3/es not_active Expired - Lifetime
- 2000-12-06 EP EP00984691A patent/EP1244693B1/en not_active Expired - Lifetime
- 2000-12-06 NZ NZ520762A patent/NZ520762A/en active Application Filing
- 2000-12-06 MX MXPA02005626A patent/MXPA02005626A/es unknown
- 2000-12-06 CA CA002396739A patent/CA2396739A1/en not_active Abandoned
- 2000-12-06 DE DE60020997T patent/DE60020997T2/de not_active Expired - Fee Related
- 2000-12-06 WO PCT/CA2000/001445 patent/WO2001042281A1/en not_active Ceased
- 2000-12-06 JP JP2001543578A patent/JP2003516417A/ja not_active Withdrawn
-
2002
- 2002-06-04 US US10/162,004 patent/US7442763B2/en not_active Expired - Lifetime
- 2002-07-19 ZA ZA200205795A patent/ZA200205795B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1244693A1 (en) | 2002-10-02 |
| US20030017988A1 (en) | 2003-01-23 |
| WO2001042281A1 (en) | 2001-06-14 |
| DE60020997D1 (de) | 2005-07-28 |
| NZ520762A (en) | 2005-02-25 |
| JP2003516417A (ja) | 2003-05-13 |
| ES2246915T3 (es) | 2006-03-01 |
| AU2134001A (en) | 2001-06-18 |
| AU784630B2 (en) | 2006-05-18 |
| DE60020997T2 (de) | 2006-05-24 |
| CA2396739A1 (en) | 2001-06-14 |
| MXPA02005626A (es) | 2004-09-10 |
| EP1244693B1 (en) | 2005-06-22 |
| US7442763B2 (en) | 2008-10-28 |
| ZA200205795B (en) | 2007-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60020997D1 (de) | Verbindungen zur behandlung von abnormaler glomerularer filtration, patent ductus arteriosus und osteoporosis | |
| BG107697A (en) | Ep4 receptor selective agonists in the treatment of osteoporosis | |
| CL2003001743A1 (es) | Compuestos derivados de leucinamida, inhibidores de la cisteina proteasa; composicion farmaceutica; procedimiento de preparacion de la composicion farmaceutica; y su uso en el tratamiento de la osteoporosis, enfermedad de paget's, peridontal, perdida | |
| AP2001002357A0 (en) | EP4 receptor selective agonists in the treatment of osteoporosis. | |
| ATE518532T1 (de) | Neue verwendung einer peptidklasse von verbindungen zur behandlung von diabetischem neuropathischem schmerz | |
| YU18400A (sh) | Prostaglanidin agonisti i njihova primena za tretiranje koštanih poremećaja | |
| ATE442373T1 (de) | Nukleotid- und proteinsequenzen von delta-genen von vertebraten und darauf basierende methoden | |
| ATE428413T1 (de) | Neue verwendung von peptidverbindungen zur behandlung ovn zentralen neuropathischen schmerzen | |
| ATE349226T1 (de) | Verwendung von verbindungen die alpha2- antiplasmin in vivo reduzieren zur herstellung einer zusammensetzung zur behandlung ischämischer schlaganfälle | |
| DE60129518D1 (de) | Verwendung von einem Vasopressin-Antagonisten wie Conivaptan zur Herstellung eines Medikaments für die Behandlung der pulmonalen Hypertension | |
| MXPA02010458A (es) | Peptido modulador del receptor de trombopoyetina. | |
| BR0115424A (pt) | Composto, composição farmacêutica, métodos para inibir a liberação de peptìdeo beta-amilóide e/ou sua sìntese, para tratar a doença de alzheimer, para prevenir a doença de alzheimer, e para inibir o progresso da doença de alzheimer, processos para preparar o composto, e para preparar lactamas, e, uso do composto | |
| DE02748548T1 (de) | Calcium-l-threonat zur prävention oder behandlung von knochenfrakturen | |
| AU2003251729A8 (en) | Use of antibodies against flt-1 for the treatment of osteoporosis | |
| DE60232140D1 (de) | Zusammensetzung zur prävention und/oder behandlung von verändertem knochenmetabolismus | |
| ATE344673T1 (de) | Tripepide und tripepdid-derivte zur behandlung von neurodegenerativen erkrankungen | |
| BRPI0412477A (pt) | aperfeiçoados polipeptìdeos de interferon-beta-1b recombinantes humanos | |
| DE60042171D1 (de) | Faktor viii oder von willebrand faktor zur behandlung von thrombopathie assoziierenden hämorrhagischen erkrankungen | |
| ATA187398A (de) | Pharmazeutisches präparat enthaltend einen rezeptor-antagonisten zur behandlung von blutgerinnungsstörungen | |
| MX9800801A (es) | Proteina mp52 arg humana. | |
| TR200101090T2 (tr) | Sertralin ağız konsantratı | |
| ATE368476T1 (de) | Neuropeptid-y1-rezeptor-bindende verbindungen zur behandlung und diagnose von krebserkrankungen | |
| ATE428692T1 (de) | 24-schwefel-substituierte 1-alpha-25-dihydroxy- vitamin-d3-analogen | |
| ATE272651T1 (de) | Verbindungen mit wachstumshormon-freisetzender eigenschaft | |
| MD621Z (ro) | Metodă de colecistectomie laparoscopică la pacienţii cu ciroză hepatică |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |